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1 Introduction
 CD4+CD25+Foxp3+ regulatory T cells (Tregs) 
play an important role in the maintenance of self-
tolerance and immune homeostasis. Treg deficiency 
contributes to the development of autoimmune diseases 
and graft-versus-host disease (GVHD) after allogeneic 
hematopoietic stem cell transplantation (HSCT) 1-6）. 
CD4 Tregs and conventional CD4 T cells (Tcons) 
are derived from lymphocyte progenitor cells that 
differentiate into distinct functional subsets in the 
thymus before export to the peripheral circulation. 
As T cells differentiate and expand in the periphery, 
each T cell subset is differentially regulated and 
subjected to distinct homeostatic signals. For example, 
interleukin-2 (IL-2) is a critical regulator of Treg 
development, expansion and survival and the lack of 
IL-2 results in selective Treg deficiency 7-10）. Tregs 
constitutively express higher levels of CD25 than 
Tcons, and which forms a high-affinity receptor for 
IL-2. Since Tregs cannot produce IL-2, these cells 
need exogenous sources, such as activated effector 
Tcons, for this critical homeostatic factor 7）. Furthermore, 
as previously reported, Tregs can respond to lower 
concentrations of IL-2 than Tcons 11）. The daily 
administration of low-dose IL-2 in patients with active 
chronic GVHD results in the sustained expansion of 
Tregs without a significant increase in Tcons; a clinical 
improvement in more than 50% of patients with chronic 
GVHD also occurs 12-15）. Added to this, the selective 
effect of low-dose IL-2 therapy has been reported in 
healthy volunteers 16）, patients with hepatitis C 
virus-induced vasculitis 17）, type 1 diabetes 18, 19）, alopecia 
areata 20）, and systemic lupus erythematosus 21）. 
 Previously we also reported the mechanism 
responsible for increased Treg susceptibility to apoptosis 
through the intrinsic pathway in chronic (c)GVHD 22）. 
The intrinsic pathway involves a complex set of 
mitochondrial-associated death signaling molecules. 
Activation of the intrinsic pathway results in mitochondrial 
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outer membrane permeabilization (MOMP) and the 
release of cytochrome c 23-25）. This pathway is regulated 
by interactions between a large number of BCL2 
family proteins, which include anti-apoptotic, pro-
apoptotic and effector proteins 26）. Apoptosis via the 
intrinsic pathway is a threshold event, with some cells 
starting closer than others to the threshold. Proximity 
to the threshold of apoptosis, or apoptotic “priming”, 
can be measured using BH3 profiling 27-30）. In this 
assay, mitochondria are exposed to peptides derived 
from the BH3 (BCL2 homology 3) domains of pro-
death BCL2 family proteins. BH3 profiling provides 
an assessment of mitochondrial susceptibility to 
MOMP that integrates the functional activity of all of 
the BCL2 family proteins that regulate the intrinsic 
apoptosis pathway in individual cells. This method 
also allows us to simultaneously compare BH3 peptide-
induced mitochondrial membrane depolarization 
( “priming”) in Tregs and Tcons. 
 In the present study, we examined the mechanisms 
whereby IL-2 affects susceptibility of Tregs to apoptosis 
through the intrinsic pathway. Low-dose IL-2 (10 IU/mL) 
lowered BH3 priming and increased BCL2 expression 
in Tregs specifically. Similar effects were observed in 
Tcons, but higher concentrations of IL-2 (>100 IU/
mL) were required to increase BCL2 expression and 
decrease BH3 priming in Tcons. Staurosporine- (STS) 
induced apoptosis assays revealed that low-dose IL-2 
reduced susceptibility to apoptosis only in Tregs. To 
confirm the effects of low-dose IL-2 on Treg priming were 
mediated by BCL2, we examined the effect of ABT-199, 
a selective BCL2 inhibitor, on BH3 priming in Tregs and 
Tcons. ABT-199 enhanced priming and the spontaneous 
apoptosis of both Tregs and Tcons. IL-2 had no effect 
on ABT-199-induced priming or apoptosis in Tcons. In 
contrast, IL-2 reversed the effects of ABT-199 on Treg 
priming and apoptosis providing further evidence 
that the inhibition of intrinsic pathway apoptosis 
mediated by IL-2 in Tregs is dependent on BCL2.
2 Material and methods
2・1 Cells and cell culture
 Human peripheral blood mononuclear cells (PBMCs) 
were obtained from the blood of healthy donors by 
density gradient centrifugation (Ficoll-Paque; GE 
Healthcare, Little Chalfont, UK) and cryopreserved in 
aliquots until needed for cell sorting, flow cytometric 
analysis, and functional assays. Cells were cultured 
using media (DMEM supplemented with 10% fetal 
bovine serum [FBS], L-glutamine, 100 IU/mL penicillin 
and 100 µg/mL streptomycin) in the presence of IL-2 
(BD Biosciences, San Jose, CA, USA; 0.001 - 10000 IU/
mL).
2・2 Flow cytometric analysis of Foxp3
 PBMCs were first incubated with anti-CD3 
APC (clone SK7; eBioscience, San Diego, CA, USA), 
anti-CD4 BV570 (clone RPA-T4; BioLegend, San 
Diego, CA, USA), anti-CD25 PE-Cy7 (clone M-A251; 
BD Biosciences), and anti-CD127 BV650 (clone A019D5; 
BioLegend). Two different T-cell subsets were 
defined by antigen expression patterns as follows: 
conventional T cells (Tcons) as CD3+CD4+CD25neg-
lowCD127med-hi, and Tregs as CD3+CD4+CD25med-
hiCD127low, respectively. To detect intracellular 
Foxp3 in each subset, surface-stained PBMCs were 
suspended in fixation and permeabilization buffer 
(eBioscience), and then incubated with anti-Foxp3 
FITC (clone 236A/E7; eBioscience) or isotype-matched 
IgG-FITC (eBioscience) for 30 minutes at 4 ℃. After 
incubation and washing, stained cells were analyzed 
on a BD LSRFortessa cell analyzer using FlowJo 
7.6.1 software 31）.
2・3 Cell sorting and Treg suppression assay
 Whole bloods were incubated with Tcell 
enrichment RosetteSep (STEMCELL Technologies, 
Vancouver Canada; 50 µL/mL of whole blood) for 20 
min. Purified T cells were obtained by density gradient 
centrifugation. Purified T cells were incubated with 
the following three antibodies for 20 minutes at 
room temperature: anti-CD4 Pacific Blue (clone 
RPA-T4; BD Biosciences), anti-CD25 PE-Cy7 (clone 
M-A251; BD Biosciences), and anti-CD127 APC-
eFluor 780 (clone eBioRDR5; eBioscience). After 
incubation, cells were washed and isolated by cell 
sorting using a BD f luorescence-activated cell 
sorting (FACS) Aria II Cell Sorter (BD Biosciences) 
into Tcons and Tregs. Sorted cell populations were 
confirmed to be more than 95% pure. These sorted 
Tcons and Tregs were used for a Treg suppression 
assay. Treg suppression was assessed using a BD 
FastImmune Human Regulatory T-Cell Function Kit 
(BD Biosciences) according to the manufacturer's 
instructions. Tcons (2 ×	104) were cultured with Tregs 
in ratios of 1:1, 1:0.5, and 1:0.25. Cultures of Tcons 
alone or with Tregs were used as controls. Cells 
were activated for 7 hours using Dynabeads Human 
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T-Activator CD3/CD28 (Life Technologies, Carlsbad, 
CA, USA) in the presence of CD154 APC. Cells were 
surface stained with kit reagents: anti-CD4 FITC, 
anti-CD25 PE, anti-CD3 PerCP-Cy5.5, and anti-CD69 
PE-Cy7. The expressions of CD154 APC and CD69 
PE-Cy7 were measured using a BD LSRFortessa and 
analyzed with FACS Diva software (BD Biosciences). 
This assay was performed in triplicate.
2・4 Tetramethylrhodamine, Ethyl Ester, Perchlorate 
FACS-based BH3 profiling
 The sequences and method of synthesis of BH3-
only peptides were previously described by Certo et 
al. 32）. PBMC were profiled by using a plate-based BH3 
profiling assay previously described by Ryan et al. 27）. 
First, PBMCs or sorted cells were first stained with 
anti-CD4 Pacific Blue, anti-CD25 PE-Cy7 and anti-
CD127 APC eFluor780 in the dark at 4 ℃ for 20 min. 
After incubation, 2.4 × 106 cells were washed in 2% 
FBS/PBS and suspended in T-EB Buffer (300 mM 
trehalose, 10 mM HEPES, 80 mM potassium chloride, 
1 mM EGTA, 1 mM EDTA, 0.1% BSA and 5 mM 
succinic acid in distilled water at pH 7.4). Cell 
suspension (50 µL) was added to 50 µL of T-EB Buffer 
containing 0.002% digitonin, 10 µg/mL oligomycin and 
0.03 - 10 µM BH3 peptides (BIM 10 µM, BIM 0.03 µM, 
BID-Y 10 µM, BAD 10 µM, NOXA 10 µM, BAD 5 µM + 
NOXA 5 µM, PUMA 10 µM, BMF 10 µM, HRK 10 µM) 
for 30 minutes at room temperature. After incubation, 
12.5 µL of 22.5 µM tertamethylrhodamine, ethyl ester 
(TMRE; Invitrogen, Carslbad, CA, USA) was added and 
the cell mixture incubated for 30 min. After incubation, 
stained cells were analyzed for each T cell subset 
(Tcon and Treg) on a BD LSRFortessa cell analyzer 
using FACS Diva software (BD Biosciences). The 
percentage mitochondrial depolarization was calculated 
using the median TMRE intensity of the total population, 
with a Phycoerythrin (PE) channel signal intensity of 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
(FCCP) treated cells serving as 100% depolarization, 
and that of dimethyl sulphoxide (DMSO) treated cells 
as 0% depolarization. The following equation was used 
to calculated the percentage depolarization for each 
peptide:
 % Depolarization by peptide = 100 × [(Median PE 
of DMSO)－ (Median PE of peptide)]/[(Median PE of 
DMSO) － (Median PE of FCCP)].
2・5 Flow cytometric analysis of BCL2, BCLXL and 
MCL1
 To detect intracellular BCL2, PBMCs or sorted 
cells were first incubated with anti-CD4 Pacific 
Blue, anti-CD25 PE-Cy7, and anti-CD127 APC 
eFluor780. For BCL2 staining, cells were then washed 
twice in PBS, suspended in 100 µL of fixation/
permeabilization solution (BD Biosciences) and 
incubated for 20 minutes at 4 ℃. After fixation, cells 
were washed and incubated with anti-BCL2 PE 
(clone BCL2/100; BD Biosciences) or isotype-matched 
IgG-PE (clone MOPC-21; BD Biosciences) for 30 
minutes at 4 ℃. After incubation and washing, 
stained cells were analyzed on a FACSCanto II flow 
cytometer using FACS Diva software (BD Biosciences). 
Cell debris and doublets were excluded on the basis of 
side versus forward scatter. Relative BCL2 expression 
in each subset was calculated by dividing the mean 
fluorescence intensity (MFI) for BCL2-PE by the 
MFI for the isotype matched IgG. To detect 
intracellular BCLXL and MCL1, PBMCs or sorted cells 
were first incubated with anti-CD3 APC, anti-CD4 
BV570, anti-CD8 BV421 (clone RPA-T8; BioLegend), 
anti-CD25 PE-Cy7, and anti-CD127 BV650. For 
BCLXL and MCL1 staining, cells were then washed 
twice in PBS and suspended in 100 µL of fixation/
permeabilization solution and incubated for 20 minutes 
at 4 ℃. After fixation, cells were washed and incubated 
with rabbit anti-BCLXL Alexa Fluor 488 (clone 
54H6; Cell Signaling Technology, Danvers, MA, 
USA), rabbit IgG Isotype Control Alexa Fluor 488 
(Cell Signaling Technology) or unconjugated rabbit 
anti-MCL1 (clone Y37; EPITOMICS) for 30 minutes 
at 4 ℃. Cells stained with unconjugated antibodies 
were subsequently stained with an anti-rabbit IgG 
Fab2 Alexa Fluor 488 (Cell Signaling Technology). 
After incubation and washing, stained cells were 
analyzed on a BD LSRFortessa cell analyzer using 
FACS Diva software (BD Biosciences). The relative 
BCLXL and MCL1 expression in each subset was 
calculated by dividing the MFI by the median value 
of the MFI for the isotype matched IgG.
2・6 Staurosporine-induced apoptosis assay
 T cell subsets were cultured separately with 0.5 µM 
staurosporine (STS) 23） or medium only in 96-well 
round-bottom plates at a concentration of 1 × 105 
PBMCs or sorted cells per well. Apoptosis induction 
was measured 6 hours after the addition of STS. 
Cell death was assessed by annexin V/7-AAD co-
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staining and forward to side scatter profiles. STS-
specific cell death was calculated as follows: (percentage 
experimental cell death - percentage spontaneous cell 
death)/(100% - percentage spontaneous cell death) × 
100.
3 Results
3・1 Treg phenotype and immune regulatory function 
 To further characterize the phenotype and 
suppressive function of CD4 Tregs and Tcons in 
healthy donor samples, CD4+CD25med-hiCD127low 
Treg and CD4+CD25lowCD127hi Tcon populations 
were purified by cell sorting using the gates shown 
in Figure 1A. As shown in a representative example 
(Figure 1B), intracellular Foxp3 expression was 
examined in each population by flow cytometry and 
was found to be expressed at high levels only in the 
Treg subset. In vitro suppression assays were also 
performed with purified Tcons and Tregs using a 
FastImmune Human Regulatory T-Cell Function Kit 
(BD Biosciences). The BD FastImmuneTM kit 
measures expression of the activation markers CD154 33） 
and CD69 34） on Tcons. Reduced expression of these 
markers in the presence of Tregs can indicate Treg 
suppressive capacity. As shown in a representative 
FACS profile of CD3/CD28 stimulated Tcons only 
Figure 1. Phenotype of Tregs and Tcons, and suppressive activity of Tregs.
 (A) Representative contour plot showing expression of CD4 in the lymphocyte gate, and expression of CD25 and CD127 
in the CD4 lymphocyte gate. PBMCs were stained with anti-CD4, -CD25, and -CD127 antibodies. CD4 lymphocytes 
were isolated into CD25neg-lowCD127med-high Tcons, and CD25med-highCD127low Tregs.
 (B) Expression of Foxp3 in Tregs and Tcons. Surface-stained peripheral blood monuclear cells (PBMCs) were stained 
with intracellular anti-Foxp3 antibody or isotype IgG (filled histograms). Foxp3 expression was measured in Tcons 
(dotted line) and Tregs (solid line).
 (C-D) Functional capacity of isolated Tregs. Tcons and Tregs were purified by flow cytometric cell sorting. Expression of 
the activation markers CD154 and CD69 on effector T cells. (C) Representative fluorescence-activated cell sorting 
(FACS) profile of CD3/CD28 stimulated Tcons (D) Stimulated Tcons in the presence of Tregs (ratio 1:1). This assay 
was performed in triplicate.
Supplemental Figure 1. Apoptosis Pathways in T cell subsets 
- Healthy Donors (n=20)
 BH3 profiling - Mitochondrial membrane depolarization 
after challenge with BH3 peptides in each T cell subset 
(Tcons: light gray, Tregs: dark gray). The percentage 
depolarization was determined after challenge with 
individual peptides as indicated on the X-axis.
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(Figure 1C) and stimulated Tcons in the presence of 
Tregs (ratio 1:1). Tcon activation was inhibited by 
coculturing with autologous Tregs, indicating that 
purified Tregs maintain expected levels of suppressive 
function.
3・2 Apoptosis pathways in Tcons and Tregs
 BH3 profiling was used to compare apoptotic 
priming of Tregs and Tcons to intrinsic pathway 
apoptosis in 20 healthy donors (Figure 2A and 
Supplemental). Tregs were more primed than Tcons 
when challenged with PUMA and BMF peptides (p = 
0.00012, and p = 0.0009, respectively). We also directly 
measured the expression of anti-apoptotic proteins 
(MCL1, BCL2 and BCLXL) in Tcons and Tregs by 
flow cytometry (Figure 2B). When compared to Tcons, 
Tregs had lower levels of BCL2 (p = 0.0081). Consistent 
with the results of BH3 profiling and the differential 
expression of apoptotic proteins, STS-induced apoptosis 
of Tregs was significantly greater than that in Tcons 
(Fig. 2C; p < 0.0001). However, significant differences 
in BH3 profiling with NOXA and HRK (Figure 2A) 
were not observed, together with the expression of 
MCL1 and BCLXL. These results indicate that Tregs 
are more primed than Tcons and that the relevant 
apoptotic pathway mainly depended on BCL2.
3・3 Apoptosis pathways in T cell subsets with different 
IL-2 concentrations
 To examine the effect of IL-2 on human Tcons 
and Tregs, we studied the time course of BH3 profiling 
with PUMA in sorted Tcons and Tregs using three 
different IL-2 concentrations (10, 100, 1000 IU/mL; 
Figure 3A). Basically IL-2 decreased BH3 priming in 
both Tregs and Tcons. In Tcons, low-dose IL-2 (10 IU/
mL) showed slightly lower priming than medium only, 
while high dose IL-2 (100 and 1000 IU/mL) decreased 
BH3 priming compared with low-dose IL-2. In Tregs, 
all concentrations of IL-2 decreased BH3 priming to 
the same level. IL-2 mainly affected Tregs on day 3 and 
Tcons on day 5. We also examined BCL2 expression 
in each T cell subset (Figure 3B). In Tcons, IL-2 
increased BCL2 expression in a dose-dependent manner. 
In Tregs, 10 IU/mL IL-2 was sufficient to increase 
Figure 2. Apoptosis Pathways in T cell subsets - Healthy Donors (n=20)
 (A) BH3 profiling - Mitochondrial membrane depolarization after challenge with BH3 peptides in each T cell subset (Tcons: 
light gray, Tregs: dark gray). The percentage depolarization was determined after challenge with individual peptides 
as indicated on the X-axis. 
 (B) Expression of anti-apoptotic proteins in each T cell subset. Protein expression was measured by flow cytometry. Relative 
levels of MCL1, BCL2 and BCLXL were calculated by dividing the median mean fluorescence intensity (MFI) for 
each protein by the median MFI of the isotype control IgG. 
 (C) Apoptosis induction after in vitro stimulation with anti-staurosporine (STS) monoclonal antibody.
 *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Supplemental Figure 2. Apoptosis pathways in T cell subsets with different IL-2 concentrations
 (A) Time course of BH3 profiling: Mitochondrial membrane depolarization after challenge with BH3 peptide (NOXA) and 
expression of anti-apoptotic protein (MCL1) in Tcons. To establish the functional effects of IL-2, Tregs and Tcons were 
purified by cell sorting and cultured for 5 days with different concentrations of IL-2 (10, 100, 1000 IU/mL). 
 (B) Time course of BH3 profiling: Mitochondrial membrane depolarization after challenge with BH3 peptide (NOXA) and 
expression of anti-apoptotic protein (MCL1) in Tregs. These assays were performed in triplicate and show representative data.
Figure 3. Apoptosis pathways in T cell subsets with different IL-2 concentrations
 (A) Time course of BH3 profiling: Mitochondrial membrane depolarization after challenge with BH3 peptide (PUMA) in 
Tcons and Tregs. To establish the functional effects of IL-2, Tregs and Tcons were purified by cell sorting and 
cultured for 5 days with different concentrations of IL-2 (10, 100, 1000 IU/mL). 
 (B) Time course of expression of anti-apoptotic protein (BCL2). Mean fluorescence intensity (MFI)
 (C) Time course of apoptosis induction after in vitro stimulation with staurosporine (STS) monoclonal antibody. 
 (D) BH3 profiling and BCL2 expression using different concentrations of IL-2 (0.001 - 10000 IU/mL) at day 3. These 
assays were performed in triplicate and show representative data.
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BCL2 expression. The peak of the IL-2 effect was 
around day 3. Consistent with the results of BH3 
profiling and the expression of apoptotic proteins, 
IL-2 induced a different effect in each T cell subset 
by STS-induced apoptosis assay (Figure 3C). IL-2 
had an anti-apoptotic effect on Tcons while low-dose 
IL-2 decreased Treg apoptosis around day 3. To confirm 
the optimal IL-2 concentration, we also investigated BH3 
profiling and BCL2 using various concentrations of 
IL-2 on day 3 (Figure 3D). A high concentration 
IL-2 (100 to 10000 IU/mL) decreased BH3 priming 
in both T cell subsets. However, lower concentrations 
of IL-2 (0.01 to 10 IU/mL) decreased BH3 priming 
only in Tregs. BCL2 expression showed similar 
data. A high concentration of IL-2 (100 to 10000 IU/mL) 
increased BCL2 expression in both T cell subsets while 
a lower concentration of IL-2 (0.01 to 10 IU/mL) 
increased BCL2 expression only in Tregs. The greatest 
difference between Tcons and Tregs was observed 
using 10 IU/mL IL-2 (Figure 3D). 
3・4 BH3 priming and % apoptosis with low-dose 
IL-2 and BCL2 inhibitor 
 To confirm the effect of BCL2 with low-dose 
IL-2 (10 IU/mL), we used ABT-199, which is a potent 
and selective BCL2 inhibitor for BH3 profiling, and 
apoptosis assays (Figure 4A and 4B). In order to see 
the difference between Tcons and Tregs, we used 
only low-dose IL-2 (10 IU/mL). For BH3 profiling in 
Tcons (Figure 4A), low-dose IL-2 did not have an 
effect while BCL2 inhibitor and BCL2 inhibitor + IL-2 
induced higher BH3 priming than medium only. For 
BH3 profiling in Tregs, low-dose IL-2 decreased BH3 
priming and the BCL2 inhibitor increased BH3 
priming. In addition, BCL2 inhibitor + IL-2 showed 
the same level of priming as medium only but less BH3 
priming than BCL2 inhibitor only. A similar pattern 
was observed for the apoptosis assay (Figure 4B). In 
Tcons, the BCL2 inhibitor increased apoptosis; low-
dose IL-2 did not reverse the effect of the BCL2 
inhibitor. However, low-dose IL-2 decreased the increase 
in apoptosis induced by the BCL2 inhibitor on Tregs. 
IL-2 had no effect on ABT-199-induced priming or 
apoptosis in Tcons. In contrast, IL-2 reversed the 
effects of ABT-199 on Treg priming and apoptosis. 
4 Discussion
 IL-2 has a wide spectrum of effects on the immune 
Supplemental Figure 3. Apoptosis pathways in T cell subsets with different IL-2 concentrations
 (A) Time course of BH3 profiling: Mitochondrial membrane depolarization after challenge with BH3 peptide (HRK) and 
expression of anti-apoptotic protein (BCLXL) in Tcons. To establish the functional effects of IL-2, Tregs and Tcons 
were purified by cell sorting and cultured for 5 days with different concentrations of IL-2 (10, 100, 1000 IU/mL). 
 (B) Time course of BH3 profiling: Mitochondrial membrane depolarization after challenge with BH3 peptide (HRK) and 
expression of anti-apoptotic protein (BCLXL) in Tregs. These assays were performed in triplicate and show 
representative data.
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Figure 4. BH3 priming and apoptosis % with low-dose IL-2 (10 IU/mL) and BCL2 inhibitor
 (A) BH3 profiling with BH3 peptide (PUMA) in Tcons and Tregs. To establish the functional effects of low-dose IL-2, 
Tregs and Tcons were purified by cell sorting and cultured for 3 days with IL-2 and/or Bcl2 inhibitor. 
 (B) Apoptosis assay with anti-staurosporine (STS) in Tregs and Tcons with the same setting as above. These assays 
were performed in triplicate and show representative data.
Supplemental Figure 4. Apoptosis pathways in T cell subsets with different IL-2 concentrations
 (A) BH3 profiling with NOXA and MCL1 expression using different concentrations of IL-2 (0.001 - 10000 IU/mL) at day 3. 
 (B) BH3 profiling with HRK and BCLXL expression using different concentrations of IL-2 (0.001 - 10000 IU/mL) at day 3. 
These assays were performed in triplicate and show representative data.
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system, and plays critical roles in regulating both 
immune activation and homeostasis 35）. In a clinical 
setting, low-dose IL-2 therapy induces immune 
tolerance and improves various diseases 12, 17-20, 36）. 
These therapeutic mechanisms of low-dose IL-2 can 
be explained by the function of the IL-2 receptor. 
The IL-2 receptor consists of three distinct components: 
IL-2Rα (CD25), IL-2Rβ (CD122) and IL-2Rγ 
(CD132) 37）. These are constitutively expressed on all 
T cells and the intracellular domains of these 
components are responsible for all receptor-mediated 
signaling activity. IL-2Rβ and IL-2Rγ have low 
affinity for IL-2 and when expressed together exhibit 
moderate binding affinity for IL-2. IL-2Rα expression 
is higher on Tregs than Tcons. IL-2Rα has no 
signaling function, but expression of IL-2Rα with 
IL-2Rβ and IL-2Rγ creates a high-affinity trimeric 
receptor that is able to respond to low concentrations 
of IL-2  37）. In this study, we showed that Tregs 
responded to low-dose IL-2 (10 IU/mL) while Tcons 
needed a higher concentration of IL-2 to affect their 
BH3 profile, BCL2 expression and apoptosis. Such 
data are compatible with our previous study 13, 14）. 
 Our studies are novel in that we used BH3 profiling 
for investigating the mechanisms between Tregs 
and low-dose IL-2. In the clinic, low-dose IL-2 treatment 
expanded Tregs and induced immune tolerance 12-14）. 
This paper sought to examine the anti-apoptotic effect 
of low-dose IL-2 on Tregs. Mammalian hematopoietic 
cells may die either following ligation and multimerization 
of cell surface death receptors (extrinsic pathway of 
apoptosis) or via a pathway regulated by the BCL2 
protein family that is initiated in response to many 
stress stimuli (intrinsic pathway of apoptosis). These 
pathways converge to activate effector caspases that 
function to destroy the cell 38）. Previous studies 
examined the extrinsic pathway of apoptosis in Tregs 
and Tcons 14, 39）. However, the susceptibility of Tregs 
to apoptosis through the intrinsic pathway has not 
been thoroughly examined. The intrinsic pathway is 
equivalent to the mitochondrial pathway in that 
both respond to cellular damage that is regulated by 
BCL2 family proteins. Such proteins control MOMP 
that is considered the point of no return for apoptosis. 
This permeabilization allows the release of soluble 
proteins such as cytochrome c from the mitochondrial 
intermembrane space into the cytosol. Cytochrome c 
binds to apoptotic protease activating factor 1 and 
caspase-9 to form the apoptosome, which activates 
downstream effector caspases and triggers apoptosis 40）. 
 To identify mechanisms that regulate Treg 
susceptibility to apoptosis through the intrinsic pathway, 
we used BH3 profiling, a functional assay that measures 
mitochondrial membrane depolarization after challenge 
with a panel of BH3 peptides 27, 41, 42）. For example, BIM 
and BID BH3 peptides interact with all endogenous 
anti-apoptotic proteins, can activate the effectors 
BAX and BAK, and are used as a measure of overall 
apoptotic priming. In contrast, NOXA, PUMA and 
HRK bind with anti-apoptotic proteins but cannot 
activate BAX or BAK. Interestingly, certain BH3 
peptides interact selectively with anti-apoptotic BCL2 
family proteins. For instance, NOXA BH3 peptides 
interact selectively with MCL1 43）, the HRK BH3 
peptide that interacts selectively with BCLXL 32）. 
 In this assay, an in vitro challenge with BH3 
peptides is used to stimulate the intrinsic pathway. 
This approach provides a method for measuring 
sensitivity to apoptotic signals at the mitochondrial 
level, termed “priming”. In this study, Tregs are more 
primed than Tcons when challenged with PUMA 
only. When challenged with NOXA and HRK, 
significant differences between Tregs and Tcons 
were not observed (Supplemental). These results 
indicate that the priming of Tregs and Tcons are 
not dependent on the expression of MCL1 and BCLXL. 
We also checked the expression of MCL1, BCLXL 
and BCL2. Anti-apoptotic protein expression also 
showed that the priming of T cells was mainly 
dependent on BCL2. In addition, we measured 
functional apoptosis by STS that induces the intrinsic 
pathway of apoptosis. Collectively, such data indicate 
that Tregs are more primed than Tcons through the 
intrinsic pathway and this is dependent on BCL2 
expression. 
 We further examined whether the dose of IL-2 
influenced the level of T-cell priming. In Figure 3, 
we can see that IL-2 decreased BH3 priming in both 
T cell subsets; low-dose IL-2 (10 IU/mL) affected 
especially Tregs while high-dose IL-2 (100 to 1000 
IU/mL) also reduced Tcon priming. A difference 
between low-dose and high-dose IL-2 in BH3 priming 
was observed. Similar patterns were also observed 
in BCL2 and apoptosis assays with STS. All data 
indicated that low-dose IL-2 could distinguish Tcon 
and Treg responses but had an anti-apoptotic effect 
only in Tregs. An ultra-low-dose of IL-2 (0.01 to 1 
IU/mL) also increased BCL2 expression and reduced 
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priming only in Tregs. However, 0.01 and 0.1 IU/mL 
showed an inadequate effect, while 1 and 10 IU/mL 
IL-2 were needed to discern Tregs and Tcons in an 
in vitro setting. In the clinic, low-dose IL-2 treatment 
can expand Tregs selectively and improve several 
autoimmune diseases, however such clinical trials 
usually determine the maximum tolerated dose 
(0.33 to 3 million IU/m2 IL-2 were used in previous 
reports 12, 17-20, 36）) in order to study the safety, dosage 
levels, and response to a new treatment. The minimum 
effective dose needs to be determined because high-
dose IL-2 shows enough of an effect in both a T cell 
setting and in expanding Tcons that could worsen 
autoimmune disease. However, an ultra-low-dose of 
IL-2 can expand and allow Tregs to survive selectively.
 In this study, we also investigated the BCL2 
dependency of Treg survival by using ABT-199 
(venetoclax), a potent and selective BCL2 inhibitor 44）. 
ABT-199 disrupted BCL2-BIM but not BCLXL-
BCLXS complexes. ABT-199 selectively inhibited 
BCL2 and induced cytochrome c release, caspase 
activation, and apoptosis. ABT-199 caused tumor 
lysis syndrome in some CLL patients, with an 80% 
response rate and manageable secondary effects 45）. 
Greater BH3 priming and apoptosis was observed 
with the BCL2 inhibitor than medium only (Figure 4). 
In order to observe the difference between Tcons 
and Tregs, we used only 10 IU/mL of IL-2. BH3 
profiling in Tcons, BCL2 inhibitor and BCL2 inhibitor 
+ IL-2 induced greater BH3 priming. But in Tregs, 
IL -2 decreased BH3 priming, and the BCL2 
inhibitor increased BH3 priming. In addition, BCL2 
inhibitor + IL-2 showed less BH3 priming than BCL2 
inhibitor only. A similar pattern was also observed 
in the apoptosis assay. Overall, these data suggest 
that low-dose IL-2 can selectively inhibit priming 
and apoptosis through the intrinsic pathway in 
Tregs. In addition, the inhibition of apoptosis by IL-2 
was actually dependent on BCL2. In contrast, we 
can activate the immune response and induce an 
anti-tumor effect by decreasing Tregs if we could 
selectively administer ABT-199 to Tregs.
 In this study, mitochondrial membrane depolarization 
by BH3 profiling was studied. However, as is well known, 
many proteins and protein complexes are related to the 
apoptosis pathway. A previous study has also shown 
that the expression of programmed cell death protein 1 
regulates IL-2-induced Treg proliferation and 
prolongs Treg survival 46）. Further study is required 
to identify factors that promote the function and 
survival of Tregs for translational research.
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低用量 IL2 は BCL2 の発現を誘導することで
CD4 制御性 T細胞のアポトーシスを抑制する
松 野 鉄 平1），村 瀬 和 幸1，2），高 田 弘 一1，2），河 野 　 豊1，2），平 川 昌 宏1），






である．既報では低用量 IL-2 は Treg の増加に選択
的に作用し，自己免疫疾患の臨床症状を改善させると








異なった用量の IL-2 で培養した．Treg では低用量
の IL-2（10 IIU/ml）でプライミングは低下し BCL2
発現は増加したが，Tcon ではプライミングの低下と
BCL2 発現の増加には高用量の IL-2（>100 IIU/ml）
が必要であった．また，低用量 IL-2 は Treg におい
てのみアポトーシスへの感受性を減らすことがアポ
トーシスアッセイによって判明した．ABT-199 とい
う BCL2 選択的阻害剤は Treg と Tcon 両者のプライ
ミンブとアポトーシスを増加させる．IL2 は Treg に
おいてのみこの ABT-199 の効果を打ち消した．この
ことから Treg における IL2 による内因性アポトーシ
スの阻害が BCL2 に依存していることが判明した．
